About

Management Team

Laura Chirica, PhD

CEO

Laura Chirica has more than 20 years of experience from commercial positions in both startups and multinationals from the life sciences and diagnostics industries. Her previous positions include Chief Commercial Officer at Immunovia AB, VP Sales and Marketing at Euro Diagnostica AB (now Svar Science), Director Purification Technologies Europe at Sartorius Stedim, Global Marketing Director at Dako A/S, and Global Marketing Program Manager at GE Healthcare.

Education: PhD in Biochemistry, MSc in Biochemistry and BSc in Biotechnology.

Other significant appointments: Board director at Gradientech AB and Senzagen AB

Maximilian Ottosson

COO and co-founder

Maximilian Ottosson is one of the founders of Cellevate and led the company between 2016-2022. He has been heavily involved in the development of the company’s technology, from generation one through three. In his previous role as CEO, Maximilian was instrumental in securing the funding that has allowed Cellevate to mature to its current level. Finally, Maximilian has taken the company to its first sales, building and maintaining important relationships with both academic and industrial customers.

Education: MSc in Engineering Nanoscience

Albin Jakobsson

CTO and co-founder

Albin Jakobsson is one of the founders of Cellevate. He has been in charge of technical development since the company’s foundation in 2014. Albin has been instrumental in developing and managing Cellevates customized solution platform, resulting in several of the products in the company’s portfolio.

Education: MSc in Engineering Nanoscience

Raul Izquierdo, PhD

VP Business Development

Raúl has more than 20 years experience in the healthcare area with over 16 years in market access, health economics and business development. His previous positions include Partner and Managing director at interlid healthcare, Market Access Director South of Europe at Immunovia, Director Latin America at Sigesa, and previous scientific experience in the University of Aveiro (Portugal) and in the Spanish Council for Research (CSIC). He has also worked as a consultant with various companies such as Advanz Pharma, Vectorious, Brainomix, O2Matic, Lisapharma, Visualfy, or the Spanish Agency for industry development (CDTI) among a list of more than 100 companies and institutions in 21 different countries.

Education: PhD in Chemistry by the University of Aveiro, Portugal, Bsc in Biological Sciences by the University of Salamanca, Spain MBA at Esade Business School, Spain.

Other significant appointments: Founder at interlid healthcare sl, Business Coach at EASME/ EISMEA (European Commission), Professor (DRGs use in hospitals management) at the European University of Madrid, Spain.

Board of Directors

Mats Leifland

Chairman of the Board

Mats Leifland has more than 30 years of experience from positions in both multinationals and startups from building & construction, real estate, life sciences and tech industries. His previous positions include Assistant Corporate Treasurer at Trelleborg AB , CFO at Peab AB, CEO at Brinova Fastigheter AB and CEO at Medicon Village Science Park.

Education: BSc. in Business, Lund University

Other significant appointments: Chairman of Waltero AB and Qvantum Industries AB. Board member of BrainLit AB and Kaunis Iron AB

Mats Grahn

Board member

Mats Grahn has more than 30 years experience in top leading positions in multinationals as well as startups in life science, diagnostics and biotech industry. His previous positions include Head of Process Chromatoghrapy Systems Unit, Vice President Laboratory Separations Division and VP Product Marketing Protein Separations at GE Heathcare- now Cytiva, Corporate Vice President Marketing at Dako A/S, now part of Agilent Technologies and CEO, Immunovia AB.

Education: MSc in Engineering Physics

Bertil Lindmark

Board member

Bertil has more than 30 years experience in life science – with globally leading roles in AstraZeneca (Global Vice President for Respiratory and Immunology), Global Head of R&D at Almirall and since 2015 Chief Medical Officer in ASLAN Pharma, eTheRNA Immunotherapies and in Galecto, developing drugs in multiple therapy areas globally. Bertil is a non-executive Member of the Board at ALK-Abelló and professor at the Gothenburg University.

Education: MD PhD background and 10 years of academic medicine with specialist competence in Internal Medicine and in Gastroenterology.

Peter Jhaveri

Board member

Peter Jhaveri has served on Cellevate’s board of directors since 2019. He has held leadership positions for more than 30 years, mainly in multinational industries such as Tetra Pak and BillerudKorsnäs. This includes multiple Managing Director or similar positions based in Asia and Europe. Mr Jhaveri has also worked in various corporate boards in SMEs including Lagafors AB, 1337Partners AB, Packbridge AB and has been a partner in D3AInvestments LLP. He is also the Managing Director of the business consulting firm Growder AB.

Education: MSc in Engineering Physics and business management training at Wharton, IMD, London Business School.

Scientific and Industrial Advisors

Hans J Johansson

Hans J Johansson is Global Applications Director at Purolite Life Sciences, Llantrisant, Wales. He has spent more than 30 years in the Biotech industry. Most of the time in research and development at Pharmacia/Amersham/GE Healthcare with a special focus on design and applications of resins for large-scale chromatography. He frequently publishes in scientific journals and is the holder of more than ten patents in the area of resin design, and large-scale protein purification applications, especially in the area of Protein A resins and multi-modal chromatography. He is currently working with development and applications of novel resins for purification of Fc-fusion proteins or mRNA. 

Education:  BSc MSc Biochemistry Uppsala University, IHR Marketing Communications Program

Lars Montelius, PhD

Lars Montelius is one of the Founders of Cellevate. He is Professor Emeritus at Lund University and he is presently the Director General of INL, the International Iberian Nanotechnology Laboratory, an intergovernmental research organization headquartered in Braga, Portugal. He has more than 30 years of experience in nanotechnology research and innovation. He was during 2003-2009 Dean of the Physics Department, Science and Engineering Faculties, Lund University, during 2009-2011 the Director for Øresund University & Øresund Science Region, being a cross-border cooperation between eleven universities, three regional authorities, two countries in the Øresund Region, and during 2007-2014 the Chair of the Swedish Technical Standardization Committee on Nanotechnology.  Lars Montelius is the Past President of IUVSTA (The International Union for Vacuum Science, Technique and Applications) and Work Group Chair of EuMat, the European Technology Platform for Materials.  

Education: PhD, Solid State Physics, MSc EE. 

Other significant appointments: Founder and Director of the Board of Compacta AB, European NanoInvest AB, Embedded Nano AB, SciMont AB and Founder of WaterSprint AB.

Mats Lundgren, PhD

Senior Consultant at Phase2Phase Biopharma AB

Mats is a senior professional with more than 25 years of experience in the biopharmaceutical industry. He is currently Senior Consultant at Phase2Phase Biopharma AB. He has significant expertise in strategic development, cell culture production, purification and analytics of vaccines, cell and gene therapies and other ATMPs.

Prior to joining Phase2Phase he was the Applications Director at Cytiva/GE Healthcare and supported biopharma companies globally to produce new therapies more efficiently. He has held positions as scientist, team manager and VP at Pharmacia, AstraZeneca and smaller biotech companies.  He has also managed the teams for Cell line and Upstream Process Development for monoclonal antibodies at a major pharma company.

Education: PhD from the Karolinska Institute in Stockholm and post-doc training at Imperial College School of Medicine in London.

Fredrik Johansson, PhD

Fredrik Johansson is one of the Founders of Cellevate. He is Associate Professor at the biology department at Lund University. He has more than 20 years of experience in bionanotechnology research and education. He is presently the director of studies in Biology, coordinator for Molecular Biology and prior to that he was director of the programme Master of Science in Engineering, Engineering Nanoscience. The main focus of research concern nerve regeneration, nanoparticles in life science and biointerfaces. 

Education: PhD in cell biology, MSc in biophysics

Bo Forsberg

Bo Forsberg is a senior expert advisor and lecturer in Downstream Processing for the Pharmaceutical industry worldwide. Bo has performed high tech service for several prominent biotech companies such as GE Healthcare, Astra Zeneca, Repligen, Novo Nordisk, BioInvent, Bio-Works, Hanbon and AGC Biologics. Bo started working with chromatography 1987 at Pharmacia Diagnostics designing and performing purification methods. After 23 years within the same company including 10 years of designing equipment for Chromatography, Bo moved to BioInvent International AB as Manager over Downstream Development and Manufacturing.  Bo’s last position was Senior Technology Specialist and Subject Matter Expert at AGC Biologics AS/CMC Biologics AS as internal technical advisor worldwide. Since June 2018, Bo has been a senior consultant.

Education: Upper secondary technical school, Chemistry

Other significant appointments: Honorary Lecturer at Department of Biotechnical Engineering at University College, London, UCL. 

Jean Christophe Bourdon, PhD

Dr. Jean-Christophe Bourdon earned his PhD in cellular and molecular biology in 1997 at the Paris XI University, France. He is currently researcher and senior lecturer at the School of Medicine at Dundee University. He was co-director of the Inserm- European Associated Laboratory (Toulouse University, France) in 2006-2010 and was awarded the prestigious fellowship from Breast Cancer Campaign in 2012. He is internationally recognised to have pioneered the p53 isoform research field and is the holder of several patents for improving production of influenza viruses and vaccine seeds. His laboratory has developed diverse methods and scientific tools (antibodies, siRNA, small molecules) to detect and regulate expression of p53 isoforms in targeted cells.

Dr. Bourdon’s lab aims to decipher the molecular mechanisms of cell fate decision mediated by the p53 isoforms in response to cell signals and treatment. In translational research, Dr. Bourdon’s lab aims to establish the p53 isoforms as predictive biomarkers and to identify new therapeutic compounds targeting the p53 isoform pathways.

Education: PhD in molecular and cellular biology, Paris XI University, France

Contact us